Key Details
Price
$8.63Annual ROE
76.03%Beta
1.86Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 12, 2024Recent annual earnings:
Feb 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
May 10, 2019Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK CITY, NY / ACCESSWIRE / November 20, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / November 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violations of federal securities laws. On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company's combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine.
NEW YORK CITY, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
GAITHERSBURG, Md. , Nov. 15, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Company granted a non- qualified stock option and restricted stock units to Ruxandra Draghia-Akli, MD, PhD, its newly appointed Executive Vice President and Head of Research & Development, as a material inducement for her entry into employment with Novavax, effective as of November 11, 2024 (the "grant date").
NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violations of federal securities laws. On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company's combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine.
NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, citing lower COVID-19 vaccine uptake.
GAITHERSBURG, Md. , Nov. 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the Jefferies London Healthcare Conference.
Novavax reported a net loss of $0.76/share and $84.5M in revenue, beating estimates but cutting guidance due to lower COVID-19 vaccine sales. Revenue has declined since 2022, prompting a substantial cost reduction program set to refocus the company on 4 key value drivers. A collaboration with Sanofi offers flexibility and potential growth, allowing Novavax to focus on developing a COVID-19/influenza combination (CIC) and seasonal influenza vaccines.
FAQ
- What is the primary business of Novavax?
- What is the ticker symbol for Novavax?
- Does Novavax pay dividends?
- What sector is Novavax in?
- What industry is Novavax in?
- What country is Novavax based in?
- When did Novavax go public?
- Is Novavax in the S&P 500?
- Is Novavax in the NASDAQ 100?
- Is Novavax in the Dow Jones?
- When was Novavax's last earnings report?
- When does Novavax report earnings?
- Should I buy Novavax stock now?